F&N eyes acquisition of Penguin Random House for $8m

It will be buying Penguin's units in Singapore and Malaysia.

Singapore beverage and publishing conglomerate Fraser & Neave is the track to buying the Singapore and Malaysian distribution arms of international book publisher Penguin Random House, a company incorporated in the United Kingdom.

F&N is targeting to buy the two units for $8m, which will be payable in cash and will be funded from internal resources.

After the acquisition, Penguin Singapore and Penguin Malaysia will become indirect wholly-owned subsidiaries of F&N. The two units will also enter into a distribution agreement with Penguin Books Limited, The Random House Group Limited, Dorling Kindersley Limited, and Penguin Random House LLC.

In an announcement, F&N said that as of September 2016, the net asset value attributable to the Penguin Singapore Shares and Penguin Malaysia Shares are approximately $6.99m and $2.96m, respectively
 

Join Singapore Business Review community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

Top News

DBS and OCBC expected to deliver steady Q1 net profits
Their net interest margins will ease as a result of their Hong Kong loans.
Singapore's maritime cluster navigates towards digital, green future
Adapting to emerging challenges, such as the adoption of alternative fuels, is deemed crucial for the country's maritime sector.
SCG and A*STAR unveil joint labs for cellular immunotherapy enhancement
The partnership has a funding of nearly $30m supported under Singapore's Research, Innovation and Enterprise 2025 plan.
Healthcare